Literature DB >> 26851611

New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.

M Revest1, C Jacqueline2, R Boudjemaa3, J Caillon2, V Le Mabecque2, A Breteche2, K Steenkeste3, P Tattevin4, G Potel2, C Michelet4, M P Fontaine-Aupart3, D Boutoille5.   

Abstract

OBJECTIVE: Prosthetic vascular graft infection (PVGI) is an emerging disease, mostly caused by staphylococci, with limited data regarding efficacy of current antistaphylococcal agents. We aimed to assess the efficacy of different antibiotic regimens.
METHODS: Six different strains of MSSA and MRSA were used. We compared results of minimal biofilm inhibitory and eradicating concentrations (MBICs and MBECs) obtained with a Calgary Biofilm Pin Lid Device (CBPD) with those yielded by an original Dacron(®)-related minimal inhibitory and eradicating concentration measure model. We then used a murine model of Staphylococcus aureus vascular prosthetic material infection to evaluate efficacy of different antibiotic regimens: vancomycin and daptomycin combined or not with rifampicin for MRSA and the same groups with cloxacillin and cloxacillin combined with rifampicin for MSSA.
RESULTS: We demonstrated that classical measures of MBICs and MBECs obtained with a CPBD could overestimate the decrease in antibiotic susceptibility in material-related infections and that the nature of the support used might influence the measure of biofilm susceptibility, since results yielded by our Dacron(®)-related minimal eradicating assay were lower than those found with a plastic device. In our in vivo model, we showed that daptomycin was significantly more bactericidal than comparators for some strains of MRSA or MSSA but not for all. For the majority of strains, it was as efficient as comparators. The addition of rifampicin to daptomycin did not enhance daptomycin efficacy.
CONCLUSIONS: Despite the heterogeneity of results according to bacterial strains, these innovative models represent an option to better evaluate the in vitro efficacy of antibiotics on Dacron(®)-related biofilm S. aureus infections, and to screen different antibiotic regimens in a mouse model of PVGIs.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26851611     DOI: 10.1093/jac/dkv496

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  New Insight into Daptomycin Bioavailability and Localization in Staphylococcus aureus Biofilms by Dynamic Fluorescence Imaging.

Authors:  Rym Boudjemaa; Romain Briandet; Matthieu Revest; Cédric Jacqueline; Jocelyne Caillon; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  In Vitro Antimicrobial Susceptibility Testing of Biofilm-Growing Bacteria: Current and Emerging Methods.

Authors:  Giovanni Di Bonaventura; Arianna Pompilio
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis.

Authors:  Enea Gino Di Domenico; Sara Giordana Rimoldi; Ilaria Cavallo; Giovanna D'Agosto; Elisabetta Trento; Giovanni Cagnoni; Alessandro Palazzin; Cristina Pagani; Francesca Romeri; Elena De Vecchi; Monica Schiavini; Daniela Secchi; Carlo Antona; Giuliano Rizzardini; Rita Barbara Dichirico; Luigi Toma; Daniela Kovacs; Giorgia Cardinali; Maria Teresa Gallo; Maria Rita Gismondo; Fabrizio Ensoli
Journal:  BMC Microbiol       Date:  2019-10-21       Impact factor: 3.605

Review 4.  A Narrative Review of Experimental Models to Study Vascular Grafts Infections.

Authors:  Mathilde Puges; Fatima M'Zali; Sabine Pereyre; Cécile Bébéar; Charles Cazanave; Xavier Bérard
Journal:  EJVES Vasc Forum       Date:  2022-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.